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Background: Cell-based assays for neuromyelitis optica (NMO) diagnosis are the most sensitive and specific
methods to detect anti-aquaporin 4 (AQP4) antibodies in serum, but some improvements in their quantitative and
specificity capacities would be desirable. Thus the aim of the present work was to develop a sensitive quantitative
method for detection of anti-AQP4 antibodies that allows clear diagnosis of NMO and distinction of false labeling
produced by natalizumab treatment.
Methods: Sera from 167 individuals, patients diagnosed with NMO (16), multiple sclerosis (85), optic neuritis (24),
idiopathic myelitis (21), or other neurological disorders (13) and healthy controls (8), were used as the primary
antibody in an immunofluorescence assay on HEK cells transfected with the M23 isoform of human AQP4 fused
with enhanced green fluorescent protein. Cells used were freshly transfected or stored frozen and then thawed just
before adding the serum.
Results: Microscopic observation and fluorescence quantification produced similar results in fresh and frozen
samples. Serum samples from patients diagnosed with NMO were 100% positive for anti-AQP4 antibodies, while
all the other sera were negative. Using serum from patients treated with natalizumab, a small and unspecific
fluorescent signal was produced from all HEK cells, regardless of AQP4 expression.
Conclusions: Our cell-based double-label fluorescence immunoassay protocol significantly increases the signal
specificity and reduces false diagnosis of NMO patients, especially in those receiving natalizumab treatment. Frozen
pretreated cells allow faster detection of anti-AQP4 antibodies.
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Neuromyelitis optica (NMO) is an inflammatory demye-
linating disease of the central nervous system (CNS) that
primarily affects the optic nerves and spinal cord [1,2].
Although for long time it was considered a variant of
multiple sclerosis (MS), new pathological and serological
tests have helped to identify the disorder as a different
disease [3]. Lennon and colleagues [4] provided the main
evidence for this distinction when they discovered specific* Correspondence: irusta@us.es
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article, unless otherwise stated.immunoglobulins in the serum of NMO patients (NMO-
IgG) that were usually absent in classical forms of MS.
The antigen recognized for NMO-IgG is aquaporin-4
(AQP4), the most abundantly expressed aquaporin in the
CNS [4-8], highly localized in astrocyte membranes facing
blood vessel capillaries and in ependymal cells that line
the cerebrospinal fluid-filled ventricles and layer of the
meninges surrounding the brain and spinal cord [7].
Recent studies have found convincing evidence of a dir-
ect involvement of AQP4 autoantibodies in the devel-
opment of NMO disease [5,9-11]. Magnetic resonance
imaging (MRI) in NMO patients indicates that most af-
fected areas coincide with those with higher AQP4 ex-
pression [5]. Histopathological lesions observed in theCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this









Group 1: NMO 16 13/3 55.02 +/- 9.80
(40-63)
Group 2: MS 85 60/25 39.43 +/-9.40
(18-76)
- Relapsing-remitting MS 72
- Secondary progressive MS 3
- Primary progressive MS 10
Group 3: idiopathic ON 24 17/7 35.01 +/- 11.39
(14-62)
-Isolated episode 15
-Recurrent idiopathic ON 9
Group 4: idiopathic
myelitis
21 14/7 46.30 +/- 14.27
(21-68)
-Isolated episode: 18
> 3 vertebral segments 9
≤ 3 vertebral segments 9
-Recurrent idiopathic myelitis 3
Group 5: other
neurological disorders
13 7/6 50.45 +/- 6.11
(42-59)
-Myelitis associated with lupus 2
-ON associated with Sjögren
syndrome
1
-Multifocal motor neuropathy 2
-CIDP 1
-Spinal infarction 2
-Ischemic optic neuropathy 5
Group 6: healthy
controls
8 5/3 34.45 +/- 8.31
(27-50)
SD; standard deviation; NMO: neuromyelitis; MS: multiple sclerosis; ON: optic
neuritis; CIDP: chronic inflammatory demyelinating polyneuropathy).
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deposition of immunoglobulins and products of com-
plement activation in a vasculocentric pattern that co-
incides with the normal distribution of AQP4 [5,12,13].
Protocols commonly used for NMO diagnosis include
MRI studies that are able to identify longitudinally ex-
tensive spinal cord lesions extending over three verte-
bral segments [14,15], with optic nerve involvement
and brain lesions in areas of high AQP4 expression
[14]. However, the discovery that anti-AQP4 IgG anti-
bodies were present in serum of patients with NMO [4]
has revolutionized the diagnosis criteria for this disease
and allows more specific treatments that may help re-
duce the frequency of new relapses.
At least five different methods have been described for
detection of anti-AQP4 antibodies in serum of patients
[16-25]. Some approaches involve incubation of the serum
with mouse brain slices and the signal, well fluorescent or
peroxidase, comes from a secondary antibody that recog-
nizes the AQP4 IgG bound to AQP4 [3,4,16,20]. Other as-
says allow the detection of antibodies by incubation of
serum with extracts in which AQP4 is labeled with either
radioactive or fluorescent tags prior to the precipitation
step [20,21]; and also enzyme-linked immunosorbent as-
says are being used to detect AQP4 antibodies in patient
serum [23,24]. Finally, a cell-based assay initially described
as proof of the identification of AQP4 as specific antigen
target in NMO positive serum, is nowadays extensively
used for routine diagnosis [21,25].
In the present work, we adapted this last method, de-
veloping a protocol that combines expression of an
AQP4-enhanced green fluorescent protein (EGFP) with
the use of a red fluorescent goat anti-human secondary
antibody. By this double labeling, we obtained a method
with extremely high sensitivity and specificity for identi-
fying NMO positive patients and that additionally en-
ables quantitative comparison of antibody levels in sera
samples tested at the same time. Moreover, the high sig-
nal specificity of the method we describe here allows
false signals to be distinguished from those produced by
sera from patients treated with natalizumab.
Methods
Subjects and serum recollection
The study population includes 167 subjects (116 female)
classified into 6 groups based on their medical diagnosis
(Table 1). Group 1 comprised 16 patients with NMO ac-
cording to the current diagnostic criteria [2]. Group 2
consisted of 85 patients with MS according to 2010-
revised McDonald criteria [26]. In relation to the MS
course, we further divided this group into 72 patients with
relapsing-remitting MS, 10 with primary progressive MS
and 3 with a secondary progressive form of the disease.
Group 3 was composed of 24 patients with optic neuritis.Twenty-one patients with myelitis formed group 4. Con-
cerning the length of the spinal cord lesion, we distin-
guished between patients whose lesions extended more
than three vertebral segments (longitudinally-extensive
myelitis) and those with shorter lesions (9 patients in each
group respectively). In addition, we categorized the pa-
tients of groups 3 and 4 depending whether they had
had an isolated episode or multiple recurrences. Group 5
comprised 13 patients with other neurological disorders
(2 patients with myelitis associated with lupus, 1 patient
with optic neuritis associated with Sjögren syndrome, 2
patients with multifocal motor neuropathy, 1 patient with
chronic inflammatory demyelinating polyneuropathy, 2
patients with spinal infarction, and 5 patients with ische-
mic optic neuropathy). Finally, group 6 was composed
of 8 healthy controls. Besides the MRI scans and the
Figure 1 Optimization of a standard protocol for NMO
diagnosis based on indirect immunofluorescence of cells
expressing AQP4. The normal cell-based assay -using AQP4 as the
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conducted for all patients in order to exclude alternative
etiologies and confirm their final diagnosis. These exams
included blood cell counts, assessment of erythrocyte
sedimentation rate, and levels of vitamins, thyroid hor-
mones, long chain fatty acids, angiotensin converting
enzyme as well as basic biochemical parameters, and im-
munological and serological tests. After collection, blood
was centrifuged at 2500 rpm (15 min, 4°C) and the serum
kept at -80°C until use.
The patients (Groups 1-5) and the healthy controls
(Group 6) were recruited by the Service of Neurology at
the Virgen del Rocío University Hospital and the IBiS,
respectively. For all participants, written consent was ob-
tained before their inclusion in the study, and demo-
graphic and clinical variables were recorded including
gender, age at inclusion in the study, clinical diagnosis
and treatments received (Table 1). The study counted
with the approval of The Ethics Committee of The Uni-
versity Hospital Virgen del Rocío (HUVR), with the
registration number 14/2010.
Plasmid construction, cell culture and cell transfection
The M23 isoform of human AQP4 was amplified by
polymerase chain reaction (PCR) from the commercial
vector pDNR-LIB cDNA using specific primers (Table 2)
and cloned into pEGFP-N1 (both Takara Bio Europe/
Clontech, France), for transfection and expression in the
HEK293T cell line. This allowed synthesis of an AQP4-
fluorescent fusion protein in which the EGFP was bound
to AQP4 by its carboxyl end. HEK cells were cultured in
Dulbecco's modified Eagle's medium with 10% fetal
bovine serum and 1% penicillin/streptomycin (37°C, 5%
CO2). Cells (2 × 10
5) were seeded in 35-mm dishes for
transfection with Lipofectamine 2000 (Invitrogen) as
previously described [27]. Transfected cells were main-
tained for 25-30 passages until the fluorescence signal of
AQP4 expression decreased to below 90%.
Immunofluorescence assay and signal quantification
Based on previous methods [18], we developed a simple
quantitative protocol that would allow us to follow
changes in anti-AQP4 antibodies in the serum of patients.
We started by performing a double blind assay in whichTable 2 Primers for PCR amplification of full-length
human aquaporin 4 (hAQP4)
Gene Primer sequences




Primers were designed using the Primer Express software (Applied-Biosystems).
Sequences of restriction enzymes used for cloning purpose are indicated:
CTCGAG: Xho1 and CCCGGG: Xma1.serum from 20 patients kindly provided by Dr. A. Saiz
[16] were re-tested with our assay confirming the original
diagnosis in all cases. Then, immunofluorescence assays
were performed on cells plated and transfected 24 h be-
fore the basic assay (without freezing) or/and cells identi-
cally treated up to the blocking step, but stored at -80°C
(frozen) until incubation with the serum (short assay).
The steps of the two immunofluorescence assays are
shown in Figure 1. Cells were washed with phosphate
buffered saline (PBS)-Ca++-Mg++ and fixed with 3% para-
formaldehyde in PBS for 5 min, followed by four washes
in PBS. They were then permeabilized with triton 0.1% in
PBS (PBTx, 5 min) and blocked using 10% FCS with
1 mg/ml BSA in PBTx (1 h). For the protocol using frozen
cells, 10% dimethyl sulfoxide (DMSO) was added to the
blocking solution before sealing the plate with parafilm.
Afterwards, cells were incubated for 1 h with the patient’s
serum (1:50 dilution), followed by another hour of incuba-
tion with Alexa Fluor 568 goat anti-human secondary
antibody. Nuclei were stained with 4’, 6’-diamidino-2-
phenylindole (DAPI, 1:1000). A Leica DM IRBE confocal
microscope was used to take five random images (40×)
per sample and NIH ImageJ software used for densitomet-
ric analysis of the fluorescence.antigen target in NMO-IgG detection- starts with culturing the cells
and transfecting them with an AQP4 vector to achieve expression
of the protein, before initiating the immunocytochemistry protocol
itself. Then, standard procedures of fixation, permeabilization and
blocking are performed before incubation with the primary and
secondary antibodies, in a protocol that would take approximately
20 days. On the other hand, frozen cells overexpressing AQP4 can
be stored, for a considerable time, at -80°C just after the blocking
step, and be used for continuation of the immune protocol on
receiving a patient’s serum, producing equivalent results in only
3 days.
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RNA was extracted from HEK cells with Trizol (Invitrogen)
and reverse transcribed using the SuperScript II Reverse
Transcriptase kit (Invitrogen). Quantitative PCR analysis
was performed in an ABI Prism 7500 Sequence Detection
System using SYBR Green PCR Master mix (both from
Applied Biosystems, Warrington, UK) and conditions
recommended by the manufacturer. Primer sequences
are indicated in Table 3. Cyclophilin and β-actin were
used as housekeeping genes to normalize for differences
in RNA input amounts, and data was represented with
respect to wild-type HEK cells. Melting curve analysis
showed a single sharp peak at the expected melting
temperature for all samples.
Statistical analysis
Data are presented as mean ± standard error of the mean,
and all statistical analyses were conducted using the IBM
SPSS Statistics (IBM Corp., Armonk, NY), version 19.0.
Data with a non-normal distribution were analyzed using
analysis of variance (ANOVA) for nonparametric data,
using the Kruskal-Wallis H or Mann-Whitney U tests for
two or more than two groups, respectively.
Results
Optimization of an immunofluorescence protocol for
detection of anti-AQP4 antibodies
The fluorescent protein (human AQP4-EGFP) allowed
direct visualization of the AQP4 cellular distribution in
HEK-transfected cells. Transfection efficiency was always
above 90%. Direct green fluorescence labeling of AQP4-
expressing cells showed a spotty distribution (Figure 2A),
resembling patches of the orthogonal array pattern char-
acteristic of this protein [28,29]. Indirect immunofluor-
escence reaction of cells with a positive control serum
(C+) showed an almost identical distribution of the red
fluorescent labeling produced by the anti-human-IgG
secondary antibody (Figure 2B) confirming the presence
of anti-AQP4 antibodies in the serum.
Using this basic protocol, we then analyzed serum from
the 167 individuals included in this study. Representative
examples of fluorescence photographs of four different
serum samples are shown in Figure 3A and the quantitativeTable 3 Primers for qRT-PCR analysis of integrin α4
Gene Forward primer sequence Reverse primer sequence












Primers were designed using the Primer Express software
(Applied Biosystems).analysis of 16 samples is presented in Figure 3B. Fluores-
cence is not visible in either the negative control (C-) serum
or in serum from a MS patient (Figure 3A), consistent
with detection of weak fluorescence signals from both
types of sera (Figure 3B). By contrast, strong fluores-
cence signals (p < 0.01) were observed both in the posi-
tive control (C+) serum and serum from a newly
diagnosed NMO patient (sample # 5136658). A high
fluorescence value in these two types of sera again evi-
denced perfect correspondence between the qualitative
microscopic observation and the numerical quantifica-
tion from the densitometric analysis. These findings
confirmed the direct correlation between detection of
anti-AQP4 antibodies and a clinical diagnosis of NMO.
Moreover, NMO antibodies were not detected in any of
the patients diagnosed with pathologies other than
NMO or in healthy controls. Quantitative analysis from
immunofluorescence assay comparing all groups is shown
in Additional file 1: Figure S1.
Comparative analysis of immunofluorescence assay using
fresh and frozen cells
To develop a rapid diagnosis protocol, the basic im-
munofluorescence assay was performed using in parallel
fresh and frozen transfected cells. A representative ex-
ample of the comparative analysis is shown in Figure 4,
where similar results are obtained with the two proto-
cols. The green fluorescent signal detected in either
fresh (Figure 4A) or frozen (Figure 4B) cells expressing
AQP4-EGFP was similar and so was the fluorescent sig-
nal (red) coming from the secondary antibody (anti-IgG)
that recognized the anti-AQP4, leading in both cases to
similar merged fluorescent images (orange). A summary
of the quantitative analysis obtained for 10 different sera,
5 NMO positive and 5 NMO negative, is shown in
Figure 4C (fresh) and 4D (frozen). With both protocols,
all patients negative for NMO antibodies showed lower
levels of fluorescence (** p < 0.01) than those obtained
with the C + serum, whereas signals from positive sera
were not statistically different to those from C + serum.
Overall, less fluorescence was observed when frozen
cells were used, but differences between NMO positive
and negative samples were qualitatively maintained in
both cases.
Positivity of serum from natalizumab-treated patients
Using the basic immunofluorescence protocol, we dis-
covered a distinctive labeling pattern in serum from a
subgroup of patients, who we later confirmed were all
on natalizumab or had received this treatment within
the 6 months prior to blood sample collection (Table 4).
As can be observed in Figure 5A, cells expressing
AQP4-EGFP (green, left column) showed a consistently
high fluorescent signal, while incubation with the serum
Figure 2 Immunofluorescence assay in HEK cells. Co-localization of fluorescent labeling was detected in cells expressing AQP4-EGFP when
a direct fluorescence signal was observed (A) or when serum from an NMO patient was used as the primary antibody (NMO-IgG) in an
immunoassay (B).
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cence (red, middle column) detectable across all cells
present in the plate, regardless of whether or not they
were expressing the AQP4 protein, and NMO+ serum
exclusively labelled cells with high expression of AQP4
(red, center photograph). Merging fluorescence images
(orange, right column) reveals strong overlapping of signals
only when NMO+ serum was used. By contrast, when
natalizumab serum was used fluorescence signals were sep-
arated and merged images did not reveal overlapping of
the signal over the same cells, evidencing a nonspecific im-
mune signal. In the C- serum, absence of red labeling dem-
onstrated lack of anti-AQP4 IgG. A summary of the
quantitative analysis obtained for 14 different sera, 7 NMO
negative, 6 with natalizumab labeling and 1 NMO +
is represented in Figure 5B. All patients negative for
NMO antibodies showed lower levels of fluorescence
(*** p < 0.001) than the value for the C + serum. Statistically
significant differences were observed between serum from
natalizumab-treated patients and C + serum (** p < 0.01)
and also between serum from NMO- and natalizumab-
treated patients (** p < 0.01).
Discussion
Nowadays, the detection of AQP4 autoantibodies (NMO-
IgG), as a serum biomarker for NMO, is an essential test
for a final diagnosis of this disease. Our initial goal was to
develop a simple detection method for use in routine
practice and we began by assessing results with immuno-
assay procedures such as Western blots and directdetection of AQP4 by immunohistochemical analysis.
After many trials, only nonspecific results were obtained
with both of these approaches, forcing us to explore alter-
natives and we started to work on a cell-based immuno-
fluorescence assay using transfected cells with high
expression of the human AQP4 M23 isoform.
The protocol we have developed and described herein
consists of a cell-based double-label fluorescence immuno-
assay, using two fluorophores with different emission
wavelengths: green, to directly visualize the expression of
human AQP4 in HEK cells; and red to visualize the
antihuman-IgG that binds to AQP4 antibodies in serum.
The co-localization of the two fluorescence signals evi-
dences the presence of NMO-IgG in serum and, therefore,
represents a specific reaction that confirms the NMO posi-
tive diagnosis. Only 16 of all the individuals analyzed had
autoantibodies for AQP4 in their serum and therefore
had an NMO positive diagnosis. Notably, quantification
of fluorescence signals obtained with sera from these 16
patients also revealed high levels of NMO-IgG, markedly
higher than levels detected in any other serum sample ana-
lyzed. Accordingly, the diagnosis of patients based on
serum immune response agreed with the diagnosis reached
by neurological examination based on the current diagnos-
tic criteria in 100% of cases [2].
While to our knowledge previously reported assays to
detect anti-AQP4 antibodies in NMO rely either on
microscopic observation of specific immune signals (visual
fluorescence or colored precipitate), or on quantification
of colorimetric, fluorescent or radioactive signals [25], the
Figure 3 Development of quantitative analysis from immunofluorescence assay. Serum from diverse patients were used as primary
antibody in an immunofluorescence assay (A). Quantification of fluorescence resulted from the densitometric analysis of fluorescence intensity
using the NIH ImageJ software taking in account the fluorescent area (B). C+, corresponds to a positive control serum in which NMO-IgG antibodies
had previously been confirmed, and C-, corresponds to a negative control serum in which the antibodies were absent. Sera from different
patients appear indicated with an identifying reference number. Significant differences (* p≤ 0.05 and ** p≤ 0.01) with respect to C- serum are
indicated. Error bars are ± SEM (n = 5).
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localization and magnitude of the fluorescent signal.
Combining these features, we have obtained a diagnos-
tic assay with high sensitivity and specificity that would
likely reduce false positive results and would improve
detection of NMO-IgG when present at low levels.
Quantification of the fluorescence intensity indicates
NMO-IgG positivity with fluorescence signals that wereclearly stronger than those obtained with controls with
this assay and the consistency in repeated measure-
ments suggests that it is a reliable and reproducible
method. So far, we have not investigated variations in
antibodies levels over time, but this is a future applica-
tion of our method and it is plausible to suppose that
the results will have predictive value for disease progres-
sion and treatment response.
Figure 4 Comparative analysis of cell immunohistochemistry results obtained using fresh or frozen cells. A and C, correspond to
experiments done on fresh cells; and B and D, on frozen cells. In A and B, the fluorescence signal from HEK cells expressing AQP4-EGFP is shown
in green (left column), and that from the secondary antibody bound to the NMO-IgG in red (middle column), while the merged image of both
fluorescent signals is shown in yellow (right column). Large magnification images are boxed. Two patients’ serum were used in the analysis;
C+, in which NMO-IgG antibodies had been confirmed previously, and C-, in which the antibodies were absent. C and D summarize the
quantitative analysis. A significant difference (** p≤ 0.01) with respect to C + serum was obtained as indicated. Error bars are ± SEM (n = 5).
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HEK cells expressing AQP4-EGFP after permeabilization,
ready to hybridize with serum as soon as sample arrive at
the laboratory, can substantially shorten the standard cell-
based fluorescent immunoassay protocol, to about 3 days,
without losing sensitivity or specificity. This would accel-
erate diagnosis from serum samples and is an approach








Yes 20 2 17*
No 147 1-6 0
*These patients were on natalizumab at the time blood samples were taken or
stopped receiving this drug less than 6 months prior to collection of the
blood sample.NMO diagnosis in hospital services where cell culture and
cell biology facilities are not easily available.
In a clinical context, another important finding in the
present study comes from experiments in which detailed
microscopic observation revealed a subgroup of sera in
which, after hybridization with AQP4 HEK-transfected
cells, a small fluorescent signal was observed from every
single cell regardless of whether there was cellular ex-
pression of the fluorescent AQP4-EGFP protein. Surpris-
ingly, the sera producing this distinctive and confusing
staining pattern, that could lead to misdiagnosis of pa-
tients as NMO positive, all came from patients that re-
ceived natalizumab treatment within the 6 months prior
to blood sample collection. Quantification of the fluores-
cence signals corroborated a positive immune reaction,
but although higher than those detected with C- (NMO-
IgG (-)), signals were clearly weaker than those obtained
with positive control sera (NMO-IgG (+)).
Figure 5 Positivity of fluorescence labeling with serum from natalizumab-treated patients. A: Shows fluorescence microphotographs from
HEK cells expressing AQP4-EGFP (left column), or the fluorescent signal after the immunoassay (middle column) with patients serum, and the
merged image of both fluorescent signals (right column). Serum from three types of patient was used in the analysis: C-, in which NMO-IgG
was absent; NMO+, in which NMO-IgG antibodies had been confirmed previously; and “Nat”, in which serum from a patient treated with
natalizumab was used. Immunofluorescence signals (red) were observed both in NMO + and Nat, although the merged image confirms exclusive
co-localization of red and green labels only in the NMO + case. All HEK cells (DAPI stained) independently of whether they express AQP4 or not
show some red fluorescence signal with Nat serum, thereby producing a signal that, though low, was above background (C-) level. B: Summarizes
the quantitative analysis. Significant statistical differences (** p < 0.01, *** p < 0.001) were observed when signals were compared to C + serum or
comparing Nat and NMO- samples (**p < 0.01). Error bars are ± SEM (n = 6-7).
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antibody that binds to the α4 chain of α4β1 and α4β7
integrins of the very late antigen (VLA)-4 in leucocytes. It
blocks leucocyte migration across the blood-brain barrier
into the CNS and with that reduces the inflammatory re-
action in patients with relapsing-remitting MS [30]. To
explain the peculiar false labeling pattern observed when
serum from natalizumab-treated patients was used, we hy-
pothesized that natalizumab antibodies were binding to
the membrane of HEK cells in an unexpected way and, in
turn, being recognized by the red fluorescent antihuman-
IgG used in the diagnostic assay. Then, using RT-qPCR,
we explored the expression of α4 chain integrin in the
HEK cells, and confirmed similar expression levels of this
protein in HEK cells whether or not they were transfected
with AQP4 (Figure 6). We directly applied an aliquot of
concentrated natalizumab (TYSABRI, 20 mg/ml), the
same formulation as that used for patient treatment, to
AQP4 HEK-transfected cells and confirmed binding of
this monoclonal antibody on cells that both did and did
not express AQP4 (Additional file 2: Figure S2).
To characterize the diagnostic assay, it was of interest
to assess the immune fluorescence-staining pattern in
sera obtained from patients who had taken natalizumab
but stopped the treatment more than 6 months before
the blood test. We found that the fluorescence-staining
pattern in these samples was indistinguishable from that
obtained with a C- serum, indicating that long periods
of time (at least 6 months) allow sufficient reduction in
circulating levels of natalizumab in serum for the false
labeling pattern to disappear.
Hence, while HEK cells offer very convenient features,
such as high transfection efficiency and levels of expressionFigure 6 Detection of α4 chain integrin in HEK cells by RT-qPCR. Perc
non-transfected HEK cells (HEK293) or in HEK cells transfected with AQP4 (H
was observed in the water control sample.of heterologous human AQP4, a drawback of using
these cells in NMO diagnostic assays is also evidenced
in the present work: specifically, the expression of in-
tegrin proteins in their membrane seems to elicit the
binding of natalizumab antibodies that, in turn, can be
recognized by human anti-IgG antibodies and result in
a false signal for NMO diagnosis. Exploring this cross
reactivity of natalizumab in different cell lines would be
important to further improve the cell-based double-
label fluorescent immunoassay procedure presented in
this work. Moreover, a similar response to the cross re-
activity observed with natalizumab could also be pro-
duced by other immunotherapies, potentially leading to
false positive diagnoses of NMO. In view of these re-
sults, we should also underline the secondary effects
some immunotherapies might have by binding to as yet
unknown targets in the human body.Conclusions
In conclusion, the use of HEK cells expressing AQP4-
EGFP that are stored frozen after the blocking step make
it possible to obtain a final result within a few days of re-
ceiving serum samples, accelerating the diagnosis of
NMO. A limitation was found in the use of HEK cells and
may be explained by false signals from the binding of
natalizumab antibodies to integrins present in HEK cell
membrane that, in turn, can be recognized by human
anti-IgG antibodies. Nevertheless, the cell-based double-
label fluorescent immunoassay protocol we present here
significantly increases the signal specificity and reduces
the likelihood of false diagnoses of NMO, especially in pa-
tients treated with natalizumab.entage of expression of integrin α4 (ITGα4) was similar in control
EK293M23) or with the empty vector (HEK293p3T). No amplification
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Additional file 1: Figure S1. Quantitative analysis from
immunofluorescence assay. Serum from patients were used as primary
antibody in an immunofluorescence assay. Quantification of fluorescence
resulted from the densitometry analysis of fluorescence level using the
NIH ImageJ software taking into account the fluorescent area. C+,
corresponds to a positive control serum in which NMO-IgG were
previously confirmed, and C-, corresponds with a negative control serum
in which the Ab was absent. Quantification of fluorescence signal from
serums of the six different groups was averaged together. Significant
differences (*** p ≤ 0.001) respect to C- serum are indicated. Error bars
are ± s.e.m (n=5). NMO: neuromyelitis; MS: multiple sclerosis; ON: optic
neuritis; ND: neurological disorders.
Additional file 2: Figure S2. Immunofluorescence assay using serum
from natalizumab treated patient vs natalizumab reagent. Green
fluorescent labeling was only detected in cells expressing EGFP-AQP4.
However similar red fluorescence labeling was observed over all cells
(expressing or not AQP4) when serum from a patient treated with
Natalizumab or directly Natalizumab reagent (Tysabri) was used as
primary antibody in the immuno assay. Nucleus were stained with DAPI.
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